Meryl Zausner Net Worth

Meryl Zausner biography

Meryl S. Zausner CPA serves as Independent Director of the Company. Ms. Zausner worked for Novartis Pharmaceuticals, Inc. (“Novartis”) from 1988 until her retirement in 2017, during which time, from April 2012 to November 2014, Ms. Zausner served as Chief Financial and Administrative Officer and a member of the Pharmaceutical Executive Committee and Global Finance Leadership Team of Novartis, in the United States. At Novartis, she helped launch the Oncology Business Unit, as well as the company’s shared services organization. Prior to serving as Chief Financial and Administrative Officer, Ms. Zausner was a member of the Novartis Global Oncology leadership team, where she contributed to the development and commercialization of therapies, including Gleevec® (imatinib). Ms. Zausner has also served on the boards of directors of Neon Therapeutics, Inc. since 2017 and the Multiple Myeloma Research Foundation since 2009. Ms. Zausner received a B.S. in Accounting and Economics from the University at Albany, SUNY.

What is the salary of Meryl Zausner?

As the Independent Director of Seres Therapeutics Inc, the total compensation of Meryl Zausner at Seres Therapeutics Inc is $75,652. There are 8 executives at Seres Therapeutics Inc getting paid more, with Eric Shaff having the highest compensation of $2,032,550.

How old is Meryl Zausner?

Meryl Zausner is 63, she's been the Independent Director of Seres Therapeutics Inc since 2018. There are 5 older and 15 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.

What's Meryl Zausner's mailing address?

Meryl's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Seres Therapeutics Inc

Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par... und Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.

What does Seres Therapeutics Inc do?

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.

Seres Therapeutics Inc executives and stock owners

Seres Therapeutics Inc executives and other stock owners filed with the SEC include:

• Eric Shaff,
  President, Chief Executive Officer, Director
• Eric D. Shaff M.B.A.,
  Pres, CEO & Director
• Thomas DesRosier,
  Chief Legal Officer, Executive Vice President and Secretary
• Matthew Henn,
  Executive Vice President, Chief Scientific Officer
• Thomas J. DesRosier,
  Chief Legal Officer, Exec. VP & Sec.
• Dr. David S. Ege Ph.D.,
  Exec. VP & Chief Technology Officer
• Richard Kender,
  Independent Director
• Kurt Graves,
  Independent Director
• Meryl Zausner,
  Independent Director
• Willard Dere,
  Independent Director
• Gregory Behar,
  Independent Director
• Dennis Ausiello,
  Independent Director
• Stephen Berenson,
  Independent Chairman of the Board
• David Ege,
  Executive Vice President, Chief Technology Officer
• Jayne Gansler,
  Chief People Officer, Executive Vice President
• Terri Young,
  Executive Vice President, Chief Commercial and Strategy Officer
• Lisa von Moltke,
  Executive Vice President, Chief Medical Officer
• Paul Biondi,
  Independent Director
• Carlo Tanzi,
  Head of Investor Relations and Corporate Communications
• John Aunins,
  Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer
• Marcus Chapman,
  Senior Vice President - Finance and Principal Financial and Accounting Officer
• Dr. John G. Aunins Ph.D.,
  Sr. Advisor
• Dr. Matthew R. Henn Ph.D.,
  Exec. VP & Chief Scientific Officer
• David A. Arkowitz M.B.A.,
  Exec. VP, CFO & Head of Bus. Devel.
• James R. Weston,
  Sr. VP of Regulatory Affairs
• Jayne M. Gansler,
  Exec. VP & Chief People Officer
• Jeff York,
  VP of HR
• Noubar Flagship Ventures Fu...,
  
• Peter Barton Hutt,
  Director
• Michele Trucksis,
  See Remarks
• David N Cook,
  See Remarks
• Noubar Afeyan,
  Director
• Health Science Us Holdings,...,
  
• Lorence H. Kim,
  Director
• Wael Hashad,
  EVP & Chief Commercial Officer
• Teresa L. Young,
  See Remarks
• Paula Cloghessy,
  See Remarks
• Marella Thorell,
  See Remarks
• Roger Pomerantz,
  President and CEO
• Kevin Horgan,
  Chief Medical Officer and EVP
• Werner Cautreels,
  Director
• Noubar Flagship Ventures Fu...,
  
• Ventures Fund Iv General Pa...,
  
• Health Ltp Fund General Par...,
  
• David Arkowitz,
  Chief Financial Officer
• Health Ltp Fund General Par...,
  
• Claire Fraser,